חוב כולל להון Biomerica (BMRA)

This price chart shows that Biomerica, Inc. (BMRA) maintains a debt-to-equity ratio of 0.61. The business relies on partnerships with pharmacies and clinics to promote rapid diagnostics. High profitability is driven by the mass sale of consumables for its proprietary test systems. The company is currently expanding its list of insurance-approved products for detecting food intolerances.

This ratio measures the proportion of borrowed funds in the asset financing structure relative to equity, determining the degree of financial leverage and bankruptcy risk. By analyzing the ratio of total debt to equity, an investor assesses the stability of Biomerica, Inc. (BMRA) during its transition from expansion via acquisitions to organic growth and profit optimization through pharmacy distribution.